Turkey National Mesothelioma Surveillance and Environmental Asbestos Exposure Control Program
- PMID: 29068368
- PMCID: PMC5707932
- DOI: 10.3390/ijerph14111293
Turkey National Mesothelioma Surveillance and Environmental Asbestos Exposure Control Program
Abstract
Malignant mesothelioma (MM) is an important health problem due to ongoing asbestos exposure. Environmental asbestos exposure leads to a high risk of MM in Turkey. The Turkish Mesothelioma Working Group and the Turkish Public Health Institute designed and performed the Turkey National Mesothelioma Surveillance and Environmental Asbestos Exposure Control Program (TUNMES-EAECP). The aim of this study was to analyze the results of the TUNMES-EAECP. Patients diagnosed with MM (code C45.0-C45.9) between 2008 and 2012 were identified. The "from case to the field" method was used to determine the villages with current or previous asbestos exposure. Special public health teams took soil samples from these villages, which were then examined using an X-ray diffractometer. Direct Standardized Average Annual Mesothelioma Incidence Rate (AMIR) and relative risk (RR) of MM were calculated. Finally, a projection on the incidence of MM between 2013 and 2033 was made. The number of confirmed MM cases was 5617 with a male to female ratio of 1.36. Mean age was 61.7 ± 13.4 (20-96) years. The median survival was eight (95% CI 7.6-8.4) months. Asbestos exposure continues in 379 villages, with 158,068 people still living in high risk areas. The standardized AMIR was 2.33/100,000 per year. The risk of MM was higher in males, in both sexes over the age of 40, in asbestos-containing provinces, and in those where the TUNMES was organized. Among the population with continuing asbestos exposure in rural areas, the number of MM cases between 2013 and 2033 was estimated as 2511. As such, the incidence of MM in Turkey is as high as in industrialized countries. Asbestos exposure in rural areas continues to be a serious problem in Turkey, which obviates the necessity for effective preventive measures.
Keywords: asbestos; environmental asbestos exposure; epidemiology; mesothelioma.
Conflict of interest statement
The authors declare no conflict of interest.
Figures




Similar articles
-
The assessment of the malignant mesothelioma cases and environmental asbestos exposure in Sivas province, Turkey.Environ Geochem Health. 2014 Feb;36(1):55-64. doi: 10.1007/s10653-013-9518-y. Epub 2013 Apr 4. Environ Geochem Health. 2014. PMID: 23553125
-
Lung cancer and mesothelioma in towns with environmental exposure to asbestos in Eastern Anatolia.Int Arch Occup Environ Health. 2006 Jan;79(1):89-91. doi: 10.1007/s00420-005-0010-6. Epub 2005 Aug 30. Int Arch Occup Environ Health. 2006. PMID: 16133524
-
Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area.Chest. 2002 Dec;122(6):2224-9. doi: 10.1378/chest.122.6.2224. Chest. 2002. PMID: 12475867
-
Malignant mesothelioma in Australia 2015: Current incidence and asbestos exposure trends.J Toxicol Environ Health B Crit Rev. 2016;19(5-6):173-189. doi: 10.1080/10937404.2016.1194254. J Toxicol Environ Health B Crit Rev. 2016. PMID: 27705544 Review.
-
[SENTIERI - Epidemiological Study of Residents in National Priority Contaminated Sites. Sixth Report].Epidemiol Prev. 2023 Jan-Apr;47(1-2 Suppl 1):1-286. doi: 10.19191/EP23.1-2-S1.003. Epidemiol Prev. 2023. PMID: 36825373 Italian.
Cited by
-
Old Habits Die Hard - Asbestos Exposure.Turk Thorac J. 2021 Sep;22(5):381-385. doi: 10.5152/TurkThoracJ.2021.0280. Turk Thorac J. 2021. PMID: 35110211 Free PMC article.
-
HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma.Dis Markers. 2019 Feb 12;2019:4183157. doi: 10.1155/2019/4183157. eCollection 2019. Dis Markers. 2019. PMID: 30891101 Free PMC article. Review.
-
Malignant pleural mesothelioma: main topics of American Society of Clinical Oncology clinical practice guidelines for diagnosis and treatment.J Thorac Dis. 2018 Jun;10(Suppl 17):S1966-S1970. doi: 10.21037/jtd.2018.04.106. J Thorac Dis. 2018. PMID: 30023092 Free PMC article. No abstract available.
-
Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma.Balkan Med J. 2022 Jul 22;39(4):246-254. doi: 10.4274/balkanmedj.galenos.2022.2022-3-26. Epub 2022 Jun 13. Balkan Med J. 2022. PMID: 35695486 Free PMC article.
-
Hospitalisation costs of malignant mesothelioma: results from the Italian hospital discharge registry (2001-2018).BMJ Open. 2021 Aug 9;11(8):e046456. doi: 10.1136/bmjopen-2020-046456. BMJ Open. 2021. PMID: 34373297 Free PMC article.
References
-
- Harber P., Gee J.B.L. Malignant Mesothelioma. Springer; New York, NY, USA: 2015. Clinicians’ approach to mesothelioma; pp. 369–379.
-
- Schuhmann M., Brims F.J.H., O’Reilly K.M.A. Asbestos-Related Lung Disease: An Update. Clin. Pulm. Med. 2011;18:265–273. doi: 10.1097/CPM.0b013e318235181f. - DOI
-
- Selçuk Z.T., Cöplü L., Emri S., Kalyoncu A.F., Sahin A.A., Bariş Y.I. Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey. Analysis of 135 cases. Chest. 1992;102:790–796. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials